Penetrating keratoplasty (PKP) is associated with an increased risk of secondary glaucoma. The development of glaucoma after PKP is an important risk factor for decreased corneal graft survival. The incidence of glaucoma after corneal transplant as well as the mechanism of developing increased intraocular pressure is reviewed in this paper. Treatments for post-PKP glaucoma include medications, laser, and surgery. The most frequent surgical glaucoma intervention is implantation of a glaucomadrainage device. Recent advances in corneal transplantation surgery may help to decrease corneal failure and the risk of developing post-keratoplasty glaucoma.
Introduction
Advances in keratoplasty surgical techniques may help to decrease the incidence of secondary glaucoma after keratoplasty surgery. The development of glaucoma after penetrating keratoplasty (PKP) can lead to devastating longterm complications, which are often sight threatening and challenging to treat. Patients with glaucoma after corneal transplants often respond poorly to medications and laser treatment and require surgical intervention not only to lower the intraocular pressure and preserve the optic nerve, but also to improve the survival of the corneal graft. This paper reviews the incidence, mechanism, and treatment of secondary glaucoma associated with corneal transplantation. Current trends in corneal transplantation and glaucoma surgery are also discussed.
Trends in corneal transplant surgery
In clinical series from around the world, primary indications for PKP include visually significant corneal scarring secondary to keratoconus and bullous keratopathy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] An important trend associated with improvements in cataract surgery techniques and the introduction of intraocular lenses has been a decline in aphakic bullous keratopathy (ABK) and an increase in pseudophakic bullous keratopathy (PBK). 8, [11] [12] [13] [14] After cataract surgery techniques evolved and phacoemulsification technology improved in the 1990s, pseudophakic corneal oedema rates have decreased. [5] [6] [7] [8] 11, [14] [15] [16] Descemet stripping automated endothelial keratoplasty (DSAEK) is a significant change in the approach to corneal transplantation involving the transplantation of an endothelial cell layer (with a thin stromal layer) vs a full thickness corneal graft in PKP. DSAEK has rapidly replaced PKP as the preferred method of corneal transplantation in eyes with PBK and Fuchs' corneal dystrophy. The Eye Bank Association of America reported an increase in corneal transplants from 48 298 to 50 122 from 2005 to 2007. In this same time period, the number of corneal endothelial transplant surgeries increased exponentially from 1429 to 14 159. 17 Increased incidence of glaucoma after penetrating keratoplasty
Irvine and Kaufman first reported a higher incidence of elevated IOP after PKP noting intraocular pressures higher than 25 mmHg in 37% of phakic eyes and 88% in aphakic eyes during the first post-operative week after corneal transplant surgery. 18 The incidence of glaucoma after PKP varies with the indication for PKP. Increased IOP develops most frequently after PKP for ABK and less frequently for eyes with Fuchs' corneal dystrophy and keratoconus. [19] [20] [21] [22] [23] [24] [25] [26] [27] In a series of 502 corneal transplant patients reported by Foulks in 1987, glaucoma developed in 18% of all patients studied: 39% in patients who were aphakic, 8% in patients who had no history of glaucoma, and 80% in patients who had a prior history of glaucoma. 19 In a series of 1122 patients from 1992, Kirkness and Ficker 23 reported that 1% of patients with keratoconus, 3% of patients with corneal dystrophies, and 29% of patients with bullous keratopathy developed elevated IOP following PKP. In 1998, Ing reported the risk of developing glaucoma post-PKP was 21% in this surgical series of 394 patients: 1% in patients with keratoconus and up to 44% in patients with PBK. 21 Other risk factors for the development of glaucoma after PKP include pre-existing glaucoma, the presence of peripheral anterior synechiae, corneal re-grafting, a history of ocular trauma, and combined PKP and cataract extraction surgery. 19, [21] [22] [23] 28, 29 Simmons reported a fourfold increased relative risk for developing glaucoma post-keratoplasty in patients with pre-existing glaucoma vs those without a prior history of glaucoma. 30 Sihota reported a post-keratoplasty incidence of glaucoma of 10.6% in his series of 747 patients, 13% of whom underwent repeat PK for a failed corneal graft. 31 
Mechanisms of post-keratoplasty glaucoma
Although increased IOP after PKP can develop in eyes with open or closed angles, peripheral anterior synchiae is present in 87% of patients post-PKP. 23, 28 Distortion of the angle, anterior and posterior to the trabecular meshwork, has also been implicated as a cause for increased IOP after PKP. Anterior to the angle, tight and long sutures cause distortion, which leads to corneal oedema and distortion of the trabecular meshwork. Posterior to the angle, loss of fixation normally afforded by the ciliary body-lens-support system allows for collapse of the TM. 32, 33 In our experience, peripheral anterior synechiae secondary to corneal transplantation leads to progressive angle closure glaucoma that is often difficult to treat with medications or laser and frequently requires surgical intervention for adequate IOP control.
Corneal transplant donor size may also affect postkeratoplasty IOP. Using oversized donor tissue may decrease the incidence of increased IOP after PKP in the early post-operative course and, possibly in the long term, but data supporting this is limited. [32] [33] [34] [35] Postsurgical glaucoma can be caused by pupillary block, iritis, haemorrhage, steroid response, malignant glaucoma, or retained viscoelastic. The use of steroids is often a double-edged sword as it is used to prevent graft rejection, but may lead to steroid response glaucoma in susceptible patients.
Medical management of post-keratoplasty glaucoma
Topical medications should be used with full awareness of their inherent risks and benefits in mind. Most topical medications have preservatives, which can lead to punctate epithelialopathy. Timolol is currently manufactured in a non-preserved formulation. Briminodine is preserved with Purite s and travoprost has a formulation preserved with Sofzia s instead of benzalkonium chloride.
The most commonly used and successful glaucoma medications are topical beta-blockers and alphaadrenergic agonists. Prostaglandins are effective in lowering the IOP, but case reports of increased incidence of inflammation associated with their use may compromise graft outcome and visual outcome if cystoid macular oedema develops. Prostaglandin agonists should also be used with caution in patients with a history of herpetic disease as Wand reported an association between latanoprost and recurrence of herpetic keratitis. 36 We do not hesitate to use prostaglandin agonists in patients with post-keratoplasty glaucoma, especially if the alternative is surgical intervention.
The use of miotics is usually ineffective and not recommended in the early post-operative period as pilocarpine causes break-down of the blood-aqueous barrier and shallows the anterior chamber with subsequent intraocular inflammation and potential development of peripheral anterior synchiae. Carbonic anhydrase inhibitors (CAIs) can be used topically or systemically. Although carbonic anhydrase enzyme is expressed by the corneal endothelium and is associated with endothelial pump function, the effect of CAIs on the graft is likely to be clinically significant only if the graft is near failure.
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Surgical management of post-keratoplasty glaucoma
Cyclodestructive procedures
Cyclodestruction was the first attempted surgical treatment for post-keratoplasty glaucoma. By ablating a portion of the ciliary body, IOP is lowered by decreasing aqueous humour production. Destruction of the ciliary body can be achieved through transscleral application of cryotherapy or transscleral or endoscopic delivery of diode, krypton or neodymium:yttrium-aluminumgarnet (Nd:YAG) laser.
Treatment success, defined as an IOP of less than 21 mmHg after a single application of laser, has recently been reported to be between 63-97%. [39] [40] [41] [42] [43] [44] However, multiple treatments may be necessary and graft failure rates have been reported to be between 17 and 44%. [39] [40] [41] [42] [43] [44] With 5-year follow-up, Beiran reported successful IOP reduction in patients with post-keratoplasty glaucoma using transscleral Nd:YAG laser in 63% of the patients. Fifty-six percent of these patients had clear grafts after 5 years. 40 More recent studies on the use of diode laser to control post-keratoplasty glaucoma show a single treatment success rate of 72% after 12 months with no cases of graft failure or phthisis bulbi. 43 In a small series, Ayyala reported no differences between trabeculectomy with mitomycin C, cyclophotocoagulation, and glaucoma shunt procedures to control glaucoma after keratoplasty. 39 
Laser trabeculoplasty
Argon laser trabeculoplasty has been reported to successfully treat post-keratoplasty glaucoma. 45 Use of this modality is often limited by the formation of PAS after keratoplasty. Poor visibility of the trabecular meshwork through the corneal transplant may also limit its use as the laser may be applied ineffectively, possibly resulting in further angle closure. Use of selective laser trabeculoplasty is also limited by visibility of the trabecular meshwork. Both procedures have limited data to support their efficacy in glaucoma following keratoplasty, and we typically do not use laser trabeculoplasty for treatment of post-keratoplasty glaucoma.
Trabeculectomy
Trabeculectomy with and without mitomycin-C has been shown to be successful in controlling intraocular pressure after keratoplasty (Table 1) . 39, [46] [47] [48] [49] [50] [51] [52] The use of anti-metabolites improves IOP control and the success of trabeculectomy. Overall, the success rates for IOP control range from 87% (14 of 16 eyes) with 1-year follow-up to 50% (12 of 24 eyes) after 2 years of follow-up based on various small studies. 46, 51 Graft clarity has been reported to be 60% after 2 years in a series of 24 patients and 62% after 22 months in a series of 26 patients. 50, 51 In postkeratoplasty patients with a trabeculectomy, glaucoma medications are frequently required for IOP control, with further glaucoma surgery often necessary.
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Glaucoma drainage implant
The most common treatment for glaucoma after keratoplasty when medications have proven to be insufficient is implantation of a tube shunt. Many studies have evaluated the efficacy of drainage implants, while evaluating graft clarity (Table 2) . [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] Glaucoma drainage implants (GDIs) are possibly the most successful modality for control of IOP after the fewest treatment procedures. 39, 44, 64 IOP control has been reported to be 62-96% after 2 years of follow-up. 54, 58 The rate of graft failure has been reported to be 35-74% after 2 years of follow-up. 59, 60 The optimal location for the drainage tube remains controversial. The most common location for tube placement is in the anterior chamber. Several authors have evaluated the success rates of different tubeplacement locations. 53, 54, 67 At 1 year, Arroyave found no difference in IOP control between the anterior chamber and pars plana tube placement, but the corneal grafts remained clear in only 48% of patients with tubes inserted into the anterior chamber vs 83% of patients with tubes placed in the pars plana. Sidoti studied 34 eyes with pars plana tube insertion and found IOP controlled in only 62% of eyes after 2 years, with clear grafts in 41% of the eyes. Sidoti also observed a higher rate of posterior segment complications as might be expected in eyes undergoing pars plana vitrectomy (allowing for pars plana tube insertion). Ritterband studied 83 eyes in which the drainage tube was either placed in the pars plana primarily or moved from the anterior chamber to the pars plana at the time of PKP. Ritterband reported 53 Placement of the tube into the vitreous cavity necessitates a complete vitrectomy with careful removal of the vitreous skirt, thereby preventing vitreous from occluding the tube. One advantage with a well-placed tube in the anterior chamber away from the cornea is convenient observation of the tube tip for occlusion at the slit lamp and easy access for laser and needling procedures to remove any tissues if the tube tip is blocked.
Graft survival in eyes with GDI placed before, simultaneously with, or after PKP has been studied and show mixed results. Kwon and Beebe reported better graft survival when the drainage implant was inserted after corneal transplantation. 62, 64 Alvarenga and Arroyave both reported no association between graft survival and timing of glaucoma drainage placement. 53, 60 Rapuano showed improved graft survival with glaucoma drainage implant surgery earlier to or at the same time as corneal transplantation. 59 The differences in these studies are likely explained by the severity of glaucoma. Patients with pre-existing glaucoma have a known risk factor for graft failure and are more likely to have uncontrolled IOP after PKP. 28, 30, 68, 69 New trends in keratoplasty surgery
As mentioned earlier, fewer keratoplasties are being performed for ABK. As aphakic patients have the highest incidence of post-keratopathy glaucoma, a trend towards reduced overall incidence of glaucoma in postkeratoplasty patients is anticipated.
The newest trend in keratoplasty is towards endothelial keratoplasty (EK) or DSAEK. Although the technique is still being refined and may undergo further advancement to involve transplantation of only Descemet's membrane instead of Descemet's membrane and stroma, the number of EK surgeries being performed is increasing rapidly. In 2005, EK represented only 3% of all transplants, whereas in 2007 EK accounted for 28% of all corneal transplant performed in the United States.
Although limited published information is currently available regarding the development of glaucoma after DSAEK, [70] [71] [72] [73] [74] [75] the incidence of glaucoma following DSAEK will likely remain low for several reasons. Fuchs' corneal dystrophy, one of the most common indications for DSAEK, has shown a low incidence of post-keratoplasty glaucoma as discussed above. In DSEAK, sutures are used only to close paracentesis(es) and the main incision, and should therefore result in less angle distortion anterior to the TM when compared with PKP. Unless improperly sized, a DSEAK donor lenticle should not contribute to crowding of the anterior chamber angle.
Air bubbles causing pupillary block glaucoma have been observed with DSAEK surgery. However, Price 73 has reported only one case in his series of 200. DSAEK has been successfully carried out in eyes with iridocorneal endothelial syndrome, in which eyes often have pre-existing glaucoma and the diseased layer of the cornea is limited to the endothelium. 74 In terms of the management of IOP after EK, the thicker central corneal thickness seen after DSAEK does not appear to give falsely elevated Goldmann applanation tonometry readings. Thus, the management of IOP after DSAEK should not be affected by the thicker central cornea. 75 The location of glaucoma drainage implant tube insertion in eyes that have already undergone or will undergo DSAEK has not been studied. Whether or not graft clarity is different when the drainage tube is placed in the pars plana or in the anterior chamber should be determined in the future. DSAEK has been suggested to have a lower incidence of graft rejection 76 and possibly a lower risk of postkeratoplasty glaucoma.
An alternative to PKP-transplant patients with a high risk of corneal graft failure is the use of a keratoprosthesis. Glaucoma has been reported to occur in between 58-72% of patients who have received a Boston keratoprosthesis. [77] [78] [79] In one series of patients with aniridia, 14 of 15 (93%) patients had pre-existing glaucoma. Glaucoma surgery was performed in 4 of 15 (27%) patients before to implantation of the keratoprosthesis. An additional four patients required post-keratoprosthesis glaucoma surgery, primarily GDI. The mechanism of glaucoma is thought to be related to eyes having had surgeries earlier due to secondary angle closure caused by inflammation or compromise of the angle due to the size and location of the keratoprosthesis back plate in relation to the iris and angle structures. In ocular surface cicatrizing diseases, thick capsules may form around the glaucoma drainage plate. A novel technique has been shown to redirect the shunt tube into extraorbital locations. 80 An advance in PKP has been the use of the femtosecond laser to cut both the host and donor buttons. [81] [82] [83] [84] [85] This new technique is an attempt to improve wound architecture and limit astigmatism as the wounds can be shaped (zig-zag, top-hat, or mushroom patterns), possibly allowing for closure with fewer sutures and/or tissue glue. In theory, the use of fewer sutures may limit angle distortion and lead to lower incidence of postoperative glaucoma. New advances may make deep anterior lamellar keratoplasty the surgery of choice for anterior corneal diseases, including keratoconus and stromal scarring. Anwar described a technique of using a 'big bubble' to separate Descemet's membrane from the corneal stroma. 86 The femtosecond laser has been utilized to cut the host and donor tissues for anterior lamellar keratoplasty and can be performed without sutures. 87 Lamellar keratoplasty has the advantage of maintaining the patient's own endothelium and will minimally affect the angle architecture. This should lead to a reduced incidence of post-keratoplasty glaucoma, at least due to architectural changes secondary to keratoplasty.
Summary
Glaucoma after corneal transplantation remains difficult to manage and a significant barrier to optimal visual outcome and corneal graft survival. Current treatments have varied, with significant side effects and complications. Although the literature includes many studies on the treatment of glaucoma after keratoplasty, many of these studies have small numbers of patients, limited follow-up, and different criteria for defining successful outcomes.
As techniques in corneal transplantation evolve, grafts should remain clear longer, with a lower incidence of glaucoma. When glaucoma does occur, it is our experience that it should be treated promptly. We typically initiate topical medical therapy and choose medications balancing risks and benefits with the patient's co-morbidities. We have found laser trabeculoplasty to be usually ineffective in treatment of post-keratoplasty glaucoma, especially if peripheral anterior synecheia is present. If surgical intervention is required, our preference is to perform GDI surgery with tube placement in accordance with the patient's anterior and posterior segment findings. When patients present with medically uncontrolled IOP and corneal opacity necessitating PKP, it is our strong preference to perform glaucoma surgery, usually GDI first to control the pressure. After the IOP and post-operative inflammation is controlled, we recommend proceeding with corneal transplant surgery. Although laser cyclodestruction has been reserved for eyes with limited visual prognosis, it should likely be given further consideration. Finally, we believe that newer corneal transplantation surgeries, such as DSAEK, will probably result in lower rates of corneal rejection secondary to improved anterior segment architectural anatomy and decreased rates of secondary glaucoma.
